Sex-specific virtual population for the prediction and assessment of arrhythmia risk
Europace · 02.06.2026 · 28 (6)
DOI: 10.1093/europace/euag133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, online erschienen am 29.05.2026. Verfasst von Fengze Sui und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Computer Science and Technology, Harbin Institute of Technology, HIT Campus, Shenzhen University Town, Nanshan District, Shenzhen 518055, G…. Hauptthemen laut MEDLINE: Arrhythmias, Cardiac, Models, Cardiovascular, Long QT Syndrome, Heart Conduction System. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, NSFC.
Abstract (Originalsprache)
Aims
Women are at higher risk of serious ventricular arrhythmias, including torsades de pointes, when repolarization reserve is reduced, but sex-stratified mechanisms and quantitative risk assessment remain challenging. We aimed to develop scalable, tissue-scale, sex-aware ventricular virtual populations to quantify and explain sex differences in inherited and acquired proarrhythmic susceptibility. Methods and results We constructed male and female virtual cohorts using a one-dimensional ventricular cable model with pseudo-electrocardiogram (pseudo-ECG), integrating sex-specific ionic conductance backgrounds and acute sex-hormone modulation. Virtual populations were filtered under multi-condition stress tests and calibrated to clinical corrected QT interval (QTc) distributions. We generated long QT syndrome types 1–3 (LQT1–3) cohorts, simulated sympathetic stress, and performed virtual drug trials for 109 compounds using multichannel block profiles at 1× effective free therapeutic plasma concentration. Proarrhythmic risk was defined by tissue-scale instability events (premature ventricular complexes, T-wave alternans, or repolarization failure). Drivers were analysed using regression and channel-sensitivity analysis, and clinical 24 h concentration-ECG data after dosing were used for external validation. The female cohorts exhibited higher simulated event risk across long QT syndrome subtypes and across multichannel drug block profiles, including drugs with <10 ms mean QTc prolongation. Female-to-male risk ratios tracked clinical risk categories. Simulated QTc time-courses and concentration-QTc trends agreed with 24 h clinical ECG data for key reference drugs.
Conclusion
Sex-aware tissue-scale virtual populations enable in silico trials that quantify proarrhythmic risk beyond mean ΔQTc, provide mechanistic drivers, and support sex-informed cardiac safety evaluation and monitoring strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Computer Science and Technology, Harbin Institute of Technology, HIT Campus, Shenzhen University Town, Nanshan District, Shenzhen 518055, Guangdong, China.
- Pengcheng Laboratory, No. 2 Xingke 1st Street, Nanshan District, Shenzhen 518000, Guangdong, China.
- Thomas Lord Department of Computer Science, Viterbi School of Engineering, University of Southern California, Los Angeles, CA 90089, USA.
ORCID-Profile: Fengze Sui, Dasen Yan, Yucheng Zhang, Wen Gao
Förderung
- National Natural Science Foundation of China
- NSFC
Zitieren
APA
Sui, F., Yan, D., Meng, X., Duan, C., Zhang, Y., Gao, W., & Song, Z. (2026). Sex-specific virtual population for the prediction and assessment of arrhythmia risk. Europace, 28(6). https://doi.org/10.1093/europace/euag133
Vancouver
Sui F, Yan D, Meng X, Duan C, Zhang Y, Gao W, et al. Sex-specific virtual population for the prediction and assessment of arrhythmia risk. Europace. 2026;28(6). doi:10.1093/europace/euag133
BibTeX
@article{Sui2026,
author = {Sui, Fengze and Yan, Dasen and Meng, Xiangbin and Duan, Chengxiang and Zhang, Yucheng and Gao, Wen and Song, Zhen},
title = {Sex-specific virtual population for the prediction and assessment of arrhythmia risk},
journal = {Europace},
year = {2026},
volume = {28},
number = {6},
doi = {10.1093/europace/euag133}
}
EUVIMED